Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 6/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9054907 | 0.89 | F2 (0.43) | F2PRSS1F10LMNAPLAT | |
| SCHEMBL9055624 | 0.86 | F2 (0.43) | F2PRSS1F10LMNAPLAT | |
| SCHEMBL9055899 | 0.86 | F2 (0.46) | F2F10 | |
| SCHEMBL9055638 | 0.82 | ITGB3 (0.41) | F2ITGB3ITGAVITGA2B | |
| SCHEMBL9054934 | 0.81 | F2 (0.46) | F2PRSS1F10LMNAPLAT | |
| SCHEMBL9054483 | 0.81 | F2 (0.44) | F2PRSS1F10LMNAPLAT | |
| SCHEMBL9055193 | 0.81 | ITGB3 (0.39) | F2ITGB3ITGAVITGA2B | |
| SCHEMBL9055345 | 0.80 | F2 (0.45) | F2PRSS1F10LMNAPLAT | |
| SCHEMBL9064351 | 0.79 | F2 (0.43) | F2PRSS1F10LMNAPLAT | |
| SCHEMBL9056463 | 0.78 | F2 (0.44) | F2PRSS1F10LMNAPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996002517-A1 | SUBSTITUTED ARYLSULFONAMIDES, THEIR PREPARATION AND USE AS THROMBIN-INHIBITING MEDICAMENTS | DR. KARL THOMAE GMBH (DE) | 1996-02-01 | — | — | WO | disclosed |